Madrigal Pharmaceuticals, Inc. (MDGL) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Jul 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MDGL SEC filings page.
Madrigal Pharmaceuticals, Inc. (MDGL) reported $1.3B in revenue over the twelve months to Jun 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue scaled sharply, yet heavy operating spending leaves the company cash-consuming and reliant on financing inflows.
The revenue ramp changed the loss shape: operating margin improved from-276.4% in FY2024 to-31.3% in FY2025, showing that scale absorbed more of the cost base. SG&A still rose to$813.8M , so the improvement came mainly from revenue covering costs rather than from shrinking operating expense.
Cash conversion improved: operating cash outflow narrowed from
The reported liquidity comparison equaled 62.3 months of FY2025 operating outflow, giving the company considerable balance-sheet flexibility on that historical measure. That flexibility coexists with a more leveraged structure: total liabilities rose from
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Madrigal Pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Madrigal Pharmaceuticals, Inc. held $983.6M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $189.6M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Madrigal Pharmaceuticals, Inc. scores 70/100 among other emerging companies.
Madrigal Pharmaceuticals, Inc. had 23M shares outstanding at the end of fiscal year 2025, against 22M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Madrigal Pharmaceuticals, Inc. scores 54/100 among other emerging companies.
Madrigal Pharmaceuticals, Inc. spent $388.5M on research and development in fiscal year 2025, which was 30.9% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Madrigal Pharmaceuticals, Inc. scores 63/100 among other emerging companies.
Madrigal Pharmaceuticals, Inc. reported revenue of $958.4M in fiscal year 2025, against $180.1M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Madrigal Pharmaceuticals, Inc. scores 95/100 among other emerging companies.
Madrigal Pharmaceuticals, Inc.'s operations used $189.6M of cash in fiscal year 2025, against $455.6M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Madrigal Pharmaceuticals, Inc. scores 67/100 among other emerging companies.
Madrigal Pharmaceuticals, Inc.'s cash, cash equivalents and investments came to $983.6M at the end of fiscal year 2025, against $656.9M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Madrigal Pharmaceuticals, Inc. scores 69/100 among other emerging companies.
Madrigal Pharmaceuticals, Inc. scores 9.02, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($11.5B) relative to total liabilities ($656.9M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Madrigal Pharmaceuticals, Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Madrigal Pharmaceuticals, Inc. reported a net loss of $288.3M while operations used $189.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Madrigal Pharmaceuticals, Inc. reported an operating loss of $300.1M against $22.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Madrigal Pharmaceuticals, Inc. generated $364.3M in revenue in Q2 2026. This represents an increase of 71.2% from the same quarter a year earlier. Against the prior quarter it is up 17.0%.
Madrigal Pharmaceuticals, Inc.'s EBITDA was -$55.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 19.4% from the same quarter a year earlier. Against the prior quarter it is up 39.4%.
Madrigal Pharmaceuticals, Inc. reported -$57.9M in net income in Q2 2026. This represents a decrease of 37.0% from the same quarter a year earlier. Against the prior quarter it is up 38.6%.
Madrigal Pharmaceuticals, Inc. earned -$1.99 per diluted share (EPS) in Q2 2026. This represents a decrease of 32.7% from the same quarter a year earlier. Against the prior quarter it is up 38.8%.
Cash & Balance Sheet
Madrigal Pharmaceuticals, Inc. generated $19.1M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 140.5% from the same quarter a year earlier. Against the prior quarter it is up 111.1%.
Madrigal Pharmaceuticals, Inc. held $292.7M in cash against $340.8M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Madrigal Pharmaceuticals, Inc.'s operating margin was -15.5% in Q2 2026, reflecting core business profitability. This is up 6.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 14.3 percentage points.
Madrigal Pharmaceuticals, Inc.'s net profit margin was -15.9% in Q2 2026, showing the share of revenue converted to profit. This is up 4.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 14.4 percentage points.
Madrigal Pharmaceuticals, Inc.'s ROE was -11.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 5.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.3 percentage points.
Not reported for Q2 2026.
Capital Allocation
Madrigal Pharmaceuticals, Inc. invested $91.2M in research and development in Q2 2026. This represents an increase of 68.6% from the same quarter a year earlier. Against the prior quarter it is down 16.1%.
Madrigal Pharmaceuticals, Inc. invested $4.3M in capex in Q2 2026, funding long-term assets and infrastructure. Against the prior quarter it is up 10.5%.
Not reported for Q2 2026.
MDGL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $364.3M+71.2% | $311.3M+126.8% | $321.1M | $287.3M+362.0% | $212.8M+1353.8% | $137.3M | N/A | $62.2M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | $4.5M | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | $132.7M | N/A | N/A |
| R&D Expenses | $91.2M+68.6% | $108.7M+146.1% | $116.3M | $174.0M+153.1% | $54.1M-23.9% | $44.2M-38.0% | N/A | $68.7M-3.1% |
| SG&A Expenses | $289.4M+47.0% | $268.5M+60.0% | $240.0M | $209.1M+94.4% | $196.9M+86.7% | $167.9M+107.8% | N/A | $107.6M+290.0% |
| Operating Income | -$56.3M-19.3% | -$92.7M-16.9% | -$59.6M | -$114.0M+2.0% | -$47.2M+71.0% | -$79.3M+47.8% | N/A | -$116.3M-18.0% |
| EBITDA | -$55.9M-19.4% | -$92.3M-17.0% | -$59.2M | -$113.6M+2.1% | -$46.8M+71.1% | -$78.9M+48.0% | N/A | -$116.0M-17.9% |
| Interest Expense | $7.9M+143.3% | $7.8M+137.2% | $8.3M | $7.5M+102.5% | $3.3M-10.7% | $3.3M-14.1% | N/A | $3.7M+5.0% |
| Net Income | -$57.9M-37.0% | -$94.4M-28.9% | -$58.6M | -$114.2M-6.8% | -$42.3M+72.2% | -$73.2M+50.4% | N/A | -$107.0M-8.3% |
| EPS (Basic) | -$1.99-32.7% | -$3.25-24.5% | -$2.03+21.6% | -$4.01+18.5% | -$1.50+78.9% | -$2.61+64.6% | -$2.59+54.4% | -$4.92+7.9% |
| EPS (Diluted) | -$1.99-32.7% | -$3.25-24.5% | -$2.03+21.6% | -$4.01+18.5% | -$1.50+78.9% | -$2.61+64.6% | -$2.59+54.4% | -$4.92+7.9% |
| Diluted Shares (Avg) | 29M+3.2% | 29M+3.4% | N/A | 29M+31.1% | 28M+31.9% | 28M+40.4% | N/A | 22M+17.7% |
Not reported in any period shown, so not listed: Income Tax.
MDGL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.2B+22.6% | $1.2B+23.1% | $1.3B+20.9% | $1.4B+26.9% | $1.0B-7.7% | $996.6M-7.9% | $1.0B+62.7% | $1.1B+351.0% |
| Current Assets | $1.2B+19.5% | $1.2B+19.7% | $1.2B+20.6% | $1.3B+26.6% | $1.0B-8.1% | $988.0M-8.0% | $1.0B+62.1% | $1.1B+351.7% |
| Cash & Equivalents | $292.7M+57.2% | $227.0M+23.6% | $198.7M+98.7% | $295.7M+27.1% | $186.2M-62.4% | $183.6M-70.5% | $100.0M+0.1% | $232.7M+275.0% |
| Short-Term Investments | $546.0M-10.6% | $585.7M-11.2% | $784.9M-5.0% | $814.1M+6.3% | $610.8M+8.5% | $659.4M+51.1% | $826.2M+54.7% | $765.9M+349.8% |
| Inventory | $99.4M+56.5% | $112.1M+102.9% | $74.8M+119.7% | $69.3M+695.4% | $63.5M+797.9% | $55.2M+6368.5% | $34.1M | $8.7M |
| Accounts Receivable | $192.3M+142.7% | $187.4M+205.0% | $134.5M+149.9% | $113.3M+271.9% | $79.2M+1048.4% | $61.4M | $53.8M | $30.5M |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $720.9M+125.7% | $683.9M+139.1% | $656.9M+128.2% | $736.7M+148.8% | $319.4M+31.6% | $286.0M+23.5% | $287.9M+22.4% | $296.1M+37.3% |
| Current Liabilities | $374.2M+90.4% | $338.3M+102.3% | $310.3M+83.3% | $391.4M+120.1% | $196.5M+57.0% | $167.2M+46.3% | $169.3M+42.8% | $177.8M+78.4% |
| Non-Current Liabilities | $346.7M+182.1% | $345.6M+191.0% | $346.6M+192.3% | $345.3M+192.0% | $122.9M+4.6% | $118.8M+1.3% | $118.6M+1.6% | $118.3M+1.9% |
| Long-Term Debt | $340.8M+187.9% | $340.3M+188.4% | $339.9M+189.1% | $339.8M+190.2% | $118.4M+1.5% | $118.0M+1.6% | $117.6M+1.8% | $117.1M+2.1% |
| Total Equity | $523.7M-24.7% | $543.5M-23.5% | $602.7M-20.1% | $625.7M-19.5% | $696.0M-18.8% | $710.6M-16.5% | $754.4M+86.1% | $777.2M+3393.0% |
| Retained Earnings | -$2.2B-17.0% | -$2.2B-16.5% | -$2.1B-16.0% | -$2.0B-16.6% | -$1.9B-17.2% | -$1.9B-26.4% | -$1.8B-34.9% | -$1.7B-42.4% |
Not reported in any period shown, so not listed: Goodwill.
MDGL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $23.3M+149.6% | -$167.4M-88.4% | -$133.5M-27.7% | $79.8M+219.2% | -$47.1M+65.1% | -$88.9M+40.4% | -$104.5M-30.7% | -$67.0M+21.1% |
| Depreciation & Amortization | $381K+1.1% | $386K+1.8% | $392K+8.0% | $358K+20.1% | $377K+41.2% | $379K+125.6% | $363K+155.6% | $298K+120.7% |
| Stock-Based Compensation | $35.4M+40.6% | $34.0M+62.5% | N/A | $26.3M+46.7% | $25.2M+3.1% | $20.9M+5.2% | N/A | $17.9M+41.4% |
| Capital Expenditures | $4.3M | $3.8M | -$390K+100.0% | $857K+10.0% | $0-100.0% | $0-100.0% | $195K-81.2% | $779K+129.8% |
| Free Cash Flow | $19.1M+140.5% | -$171.3M-92.7% | -$133.8M-27.9% | $79.0M+216.6% | -$47.1M+65.2% | -$88.9M+40.5% | -$104.7M-29.3% | -$67.8M+20.5% |
| Investing Cash Flow | $34.2M-28.5% | $192.2M+17.3% | $27.6M+157.5% | -$207.0M-2.3% | $47.9M+139.2% | $163.9M+67.1% | -$48.0M+86.8% | -$202.4M-503.2% |
| Financing Cash Flow | $3.1M+78.7% | $2.3M-73.0% | $9.0M-54.7% | $236.6M+3071.4% | $1.7M-98.7% | $8.6M-98.5% | $19.8M-95.9% | $7.5M-61.9% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
MDGL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | 96.7% | N/A | N/A |
| Operating Margin | -15.5%+6.7pp | -29.8%+28.0pp | -18.6% | -39.7% | -22.2% | -57.8% | N/A | -187.1% |
| Net Margin | -15.9%+4.0pp | -30.3%+23.0pp | -18.2% | -39.8% | -19.9% | -53.4% | N/A | -172.0% |
| Return on Equity | -11.1%-5.0pp | -17.4%-7.1pp | -9.7% | -18.3%-4.5pp | -6.1%+11.7pp | -10.3%+7.0pp | N/A | -13.8%+430.0pp |
| Return on Assets | -4.7%-0.5pp | -7.7%-0.3pp | -4.7% | -8.4%+1.6pp | -4.2%+9.7pp | -7.3%+6.3pp | N/A | -10.0%+31.5pp |
| Current Ratio | 3.20-1.9x | 3.50-2.4x | 4.01-2.1x | 3.44-2.5x | 5.11-3.6x | 5.91-3.5x | 6.10+0.7x | 5.98+3.6x |
| Debt-to-Equity | 0.65+0.5x | 0.63+0.5x | 0.56+0.4x | 0.54+0.4x | 0.170.0x | 0.170.0x | 0.16-0.1x | 0.15-5.0x |
| Asset Turnover | 0.29+0.1x | 0.25+0.1x | 0.25 | 0.21+0.2x | 0.21+0.2x | 0.14+0.1x | N/A | 0.06+0.1x |
| FCF Margin | 5.2%+27.3pp | -55.0%+9.8pp | -41.7% | 27.5% | -22.1% | -64.8% | N/A | -109.0% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals, Inc. MDGL | FY2025 | $958.4M | -$288.3M | -30.1% | $11.5B | 70/100 |
| Verona Pharma plc VRNA | FY2024 | $42.3M | -$173.4M | N/A | $9.2B | 60/100 |
| Roivant Sciences Ltd. ROIV | FY2026 | $8.3M | -$299.8M | N/A | $25.8B | 66/100 |
| Moderna, Inc. MRNA | FY2025 | $1.9B | -$2.8B | N/A | $81.1B | 31/100 |
| Halozyme Therapeutics, Inc. HALO | FY2025 | $1.4B | $316.9M | 22.7% | $12.3B | 78/100 |
Where Madrigal Pharmaceuticals, Inc. Ranks
Frequently Asked Questions
What is Madrigal Pharmaceuticals, Inc.'s annual revenue?
Madrigal Pharmaceuticals, Inc. (MDGL) reported $958.4M in total revenue for fiscal year 2025. This represents a 432.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Madrigal Pharmaceuticals, Inc.'s revenue growing?
Madrigal Pharmaceuticals, Inc. (MDGL) revenue grew by 432.1% year-over-year, from $180.1M to $958.4M in fiscal year 2025.
Is Madrigal Pharmaceuticals, Inc. profitable?
No, Madrigal Pharmaceuticals, Inc. (MDGL) reported a net income of -$288.3M in fiscal year 2025, with a net profit margin of -30.1%.
What is Madrigal Pharmaceuticals, Inc.'s EBITDA?
Madrigal Pharmaceuticals, Inc. (MDGL) had EBITDA of -$298.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Madrigal Pharmaceuticals, Inc. have?
As of fiscal year 2025, Madrigal Pharmaceuticals, Inc. (MDGL) had $198.7M in cash and equivalents against $339.9M in long-term debt.
What is Madrigal Pharmaceuticals, Inc.'s operating margin?
Madrigal Pharmaceuticals, Inc. (MDGL) had an operating margin of -31.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Madrigal Pharmaceuticals, Inc.'s net profit margin?
Madrigal Pharmaceuticals, Inc. (MDGL) had a net profit margin of -30.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Madrigal Pharmaceuticals, Inc.'s return on equity (ROE)?
Madrigal Pharmaceuticals, Inc. (MDGL) has a return on equity of -47.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Madrigal Pharmaceuticals, Inc.'s free cash flow?
Madrigal Pharmaceuticals, Inc. (MDGL) recorded an outflow of $190.0M in free cash flow during fiscal year 2025. This represents a 58.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Madrigal Pharmaceuticals, Inc.'s operating cash flow?
Madrigal Pharmaceuticals, Inc. (MDGL) recorded an outflow of $189.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Madrigal Pharmaceuticals, Inc.'s total assets?
Madrigal Pharmaceuticals, Inc. (MDGL) had $1.3B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Madrigal Pharmaceuticals, Inc.'s capital expenditures?
Madrigal Pharmaceuticals, Inc. (MDGL) invested $467K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Madrigal Pharmaceuticals, Inc. spend on research and development?
Madrigal Pharmaceuticals, Inc. (MDGL) invested $388.5M in research and development during fiscal year 2025.
What is Madrigal Pharmaceuticals, Inc.'s current ratio?
Madrigal Pharmaceuticals, Inc. (MDGL) had a current ratio of 4.01 as of fiscal year 2025, which is generally considered healthy.
What is Madrigal Pharmaceuticals, Inc.'s debt-to-equity ratio?
Madrigal Pharmaceuticals, Inc. (MDGL) had a debt-to-equity ratio of 0.56 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Madrigal Pharmaceuticals, Inc.'s return on assets (ROA)?
Madrigal Pharmaceuticals, Inc. (MDGL) had a return on assets of -22.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Madrigal Pharmaceuticals, Inc.'s P/E ratio?
Madrigal Pharmaceuticals, Inc. (MDGL) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $11.5B as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Madrigal Pharmaceuticals, Inc.'s price-to-sales ratio?
Madrigal Pharmaceuticals, Inc. (MDGL) trades at 8.9x sales, its market capitalization divided by revenue of $1.3B revenue, trailing 12 months to June 30, 2026. The market capitalization is $11.5B as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Madrigal Pharmaceuticals, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Madrigal Pharmaceuticals, Inc. (MDGL) held $983.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $189.6M over that year. Dividing the one by the other, the reported balance equals about 62 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Madrigal Pharmaceuticals, Inc.'s Altman Z-Score?
Madrigal Pharmaceuticals, Inc. (MDGL) has an Altman Z-Score of 9.02, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Madrigal Pharmaceuticals, Inc.'s Piotroski F-Score?
Madrigal Pharmaceuticals, Inc. (MDGL) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Madrigal Pharmaceuticals, Inc.'s earnings high quality?
Madrigal Pharmaceuticals, Inc. (MDGL) reported a net loss of $288.3M while operations used $189.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Madrigal Pharmaceuticals, Inc. cover its interest payments?
Madrigal Pharmaceuticals, Inc. (MDGL) reported an operating loss of $300.1M against $22.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Madrigal Pharmaceuticals, Inc.?
Madrigal Pharmaceuticals, Inc. (MDGL) scores 70 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.